01 Aug 2012, BioSpectrum Bureau , BioSpectrum
Mumbai: Indian pharmaceutical company Cipla reported a revenue growth of 23.6 percent to approximately $362 million* (Rs 2012 crore), up from approximately $294 million (Rs 1628 crore) in Q1 of the previous financial year.
Domestic revenues grew by 30.4 percent to $174.5 million (Rs 970 crore), up from $133.9 million (Rs 744 crore) during Q1 of the previous financial year.
The growth in domestic revenues was largely on account of growth in anti-asthma and anti-biotics therapy segments. Exports of formulations grew by 23 percent to $145.7 million (Rs 810 crore) the first quarter of FY 1213. However, export of APIs witnessed a drop of two percent. The growth in export revenues was primarily due to growth in anti-depressants and anti-cancer segments.
Cipla laid foundations for the Indian pharmaceutical industry back in 1935 with the vision to make India self-reliant in healthcare. Over the years Cipla has emerged as one of the most respected names not just in India but worldwide. Its state of the art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. With over 34 manufacturing units across the country, Cipla manufactures over 2000 products in 65 therapies.
* All conversions based on the rate Rs 1= $0.0179975